Research Evidence
Growth Hormone Stimulation Studies
The foundational 1984 study by Bowers and colleagues in Endocrinology demonstrated that GHRP-6 specifically elicited a dose-dependent release of GH in vitro and in vivo without concomitant release of LH, FSH, TSH, or prolactin at standard doses. Subsequent work established the saturation dose of approximately 1 mcg/kg IV, producing peak GH levels of 15 to 50 mcg/L in healthy subjects.
Leal-Cerro et al. (1998) showed that endogenous hypothalamic GHRH is required for the full GH response to GHRP-6, establishing the synergistic relationship between the two pathways and the pharmacological rationale for GHRP-plus-GHRH combination protocols.Oral Administration in Children
A 1995 study by Bellone and colleagues published in the European Journal of Endocrinology demonstrated that oral GHRP-6 retained GH-releasing activity in children with short stature. In 13 children aged 6.2 to 10.5 years, oral GHRP-6 induced a GH response with peak values of 18.8 mcg/L at 60 minutes, comparable to that elicited by intravenous GHRH. This result should be interpreted cautiously: oral bioavailability of hexapeptides is generally extremely low due to gastrointestinal degradation and poor intestinal absorption, and the finding has not been widely replicated or supported by pharmacokinetic data confirming systemic peptide absorption at meaningful levels.
Cortisol and ACTH Effects
Pena-Bello et al. (2010) studied the effects of GHRP-6, GHRH, and their combination on GH, ACTH, and cortisol in patients with type 1 diabetes mellitus. The research confirmed that GHRP-6 produces modest but measurable ACTH and cortisol elevations alongside GH release, particularly at doses above the saturation threshold.
Cardioprotective Research (Preclinical)
A significant body of preclinical research from Cuban investigators has documented cardioprotective and cytoprotective properties of GHRP-6. Berlanga-Acosta et al. (2006) demonstrated that GHRP-6 reduced myocardial necrosis by 78% and infarct thickness by 50% in a porcine model of acute myocardial infarction, acting through oxidant-scavenging mechanisms.
More recently, Sosa-Hernandez et al. (2024) showed that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage in rats by attenuating pro-oxidant activity, enhancing antioxidant reserves, protecting mitochondrial ultrastructure, and upregulating the anti-apoptotic gene Bcl-2. The cytoprotective effects extended beyond the heart to hepatocytes, renal tubular cells, bronchial epithelia, and intestinal enterocytes.
These cardioprotective properties appear to be mediated at least partly through CD36 receptor binding, independent of the GHS-R1a/GH pathway, and represent one of the most promising avenues for future GHRP-6 research.Pharmacokinetic Profile
Fernandez-Perez et al. (2013) conducted a formal pharmacokinetic study in nine healthy male volunteers, establishing a biphasic profile: a rapid distribution phase of approximately 7.6 minutes followed by an elimination phase of approximately 2.5 hours. Peak GH levels occurred within 15 to 30 minutes of administration. This biphasic profile necessitates multiple daily injections for sustained GH elevation.